BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CircuLite Nets CE Mark for HF Pump


9/5/2012 7:25:25 AM

SADDLE BROOK, N.J. and AACHEN, Germany (September 5, 2012) – CircuLite®, Inc. today announced that it has received CE Marking approval for the SYNERGY® Circulatory Support System, a micro-pump designed to halt the progression of heart failure. By working with the heart’s native pumping capacity, SYNERGY is specifically targeted for treatment of ambulatory heart failure patients (INTERMACS 4,5,6 / NYHA IIIB and early IV) who remain symptomatic despite standard medical management.

SYNERGY is approximately the size of a AA battery and is implanted superficially in a pacemaker-like pocket under the right collarbone. SYNERGY is approximately 90 percent lighter than existing ventricular assist devices (VADs), and unlike VADs, implantation of SYNERGY is faster and does not require an open-chest procedure or cardiopulmonary bypass.

CE Marking approval was based on positive clinical results from 44 patients in an ongoing, multi-center European trial, recently presented at the International Society for Heart and Lung Transplantation (ISHLT) meeting. A total of 59 patients have been implanted with the SYNERGY System in the CE Mark trial at 9 European centers.

“There is currently a gap in the treatment of heart failure, with no satisfactory options available for patients who are not responding to standard medical therapy. SYNERGY, with its small size, minimally invasive procedure and relatively fast procedure time, is ideally suited for these patients,” said Bart Meyns, M.D., Ph.D., Professor and Chief of Cardiac Surgery at Gasthuisberg University Hospital and Principal Investigator of CircuLite’s clinical study. “In my experience with this technology, the results have been remarkable. Patients typically recover from the procedure quickly and are soon after able to perform many activities that they could not do before. This technology allows me to provide a new treatment strategy for a large number of patients who previously had no definitive options.”

“The European approval of SYNERGY is a significant milestone both for CircuLite and, more broadly, for the treatment of heart failure,” said Paul Southworth, President and Chief Executive Officer of CircuLite. “SYNERGY changes the paradigm of heart failure treatment for those who are not responding to standard medical management by working as a complement to the heart’s function. The benefits are multifaceted—patients feel better, recover rapidly and are discharged quickly—which provides the potential for a cost reduction impact for hospitals. With CE Marking in place, we will begin a controlled launch of this groundbreaking advancement in select European markets.”

About the SYNERGY® Circulatory Support System

The SYNERGY Circulatory Support System is a micro-blood pump that provides up to 4.25 liters of blood per minute and reduces the heart's workload, while improving blood flow to vital organs. The system is surgically implanted using a mini-thoracotomy and is placed in a pacemaker-like pocket. In a clinical study, SYNERGY improved hemodynamics, exercise capacity and overall quality of life. SYNERGY is designed and manufactured in Aachen, Germany.

About CircuLite®

CircuLite is developing disruptive solutions to improve the treatment of heart failure. The Company’s technologies work in conjunction with the heart to enhance clinical outcomes and improve quality of life. SYNERGY®, which recently received CE Marking approval, features the smallest surgically implanted blood pump for long-term use in patients with heart failure not responding to standard medical treatment. For more information, visit our website at www.circulite.net.

CAUTION: Investigational Device. Limited by United States Law to Investigational Use Only. CircuLite® and SYNERGY® are registered trademarks of CircuLite, Inc. in the United States.

Contacts

Media:

MacDougall Biomedical Communications

Kari Watson and Cory Tromblee, 781-235-3060 kwatson@macbiocom.com or ctromblee@macbiocom.com or CircuLite, Inc.:

Gail Farnan, 201-478-7651

Vice President, Marketing



Read at BioSpace.com
Read at News Release
Read at News Release

CircuLite
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES